CORDIS
EU research results

CORDIS

English EN

Antibody-based therapy against Streptococcus pneumoniae

Project information

Grant agreement ID: 798032

Status

Ongoing project

  • Start date

    15 June 2018

  • End date

    14 June 2020

Funded under:

H2020-EU.1.3.2.

  • Overall budget:

    € 165 598,80

  • EU contribution

    € 165 598,80

Coordinated by:

UNIVERSITAIR MEDISCH CENTRUM UTRECHT

Netherlands

Objective

The pneumococcus (Streptococcus pneumoniae) is the predominant cause of community-acquired pneumonia and causes otitis media, sinusitis, meningitis and sepsis. The increased serotype replacement and antibiotic resistance, reinforces the necessity of developing alternative treatment strategies for this pathogen. Monoclonal antibodies that boost the host immune system are attractive candidates to fight the high rates of morbidity and mortality due to this important human pathogen. Antibodies recognizing bacterial surface structures could be used to trigger activation of the complement cascade and subsequent bacterial killing. However, no significant progress has been made in the direction of immune system boosting therapies against pneumococci, mainly caused by our limited insights into antibody-driven immune activation on bacteria. With this proposal, I aim to study whether complement-enhancing monoclonal antibodies can be used as treatment against pneumococci. Through a combination of advanced sequencing approaches and functional complement activation assays, I will first identify antibodies against S. pneumoniae driving potent complement activation. Then I will use my expertise in S. pneumoniae infection models to unravel whether monoclonal antibodies eliciting complement are effective in pneumococcal killing in vitro and in vivo. The work proposed represents a first systematic approach to design effective therapeutic antibodies against S. pneumoniae that function via enhanced complement activation. Altogether, a better understanding of antibody-dependent complement activation on bacteria will create new avenues for the design of new therapeutic strategies to improve both antibody therapies and vaccination strategies in diseases caused by pathogenic bacteria.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITAIR MEDISCH CENTRUM UTRECHT

Address

Heidelberglaan 100
3584 Cx Utrecht

Netherlands

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 165 598,80

Project information

Grant agreement ID: 798032

Status

Ongoing project

  • Start date

    15 June 2018

  • End date

    14 June 2020

Funded under:

H2020-EU.1.3.2.

  • Overall budget:

    € 165 598,80

  • EU contribution

    € 165 598,80

Coordinated by:

UNIVERSITAIR MEDISCH CENTRUM UTRECHT

Netherlands